Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Intra-Cellular Therapies Stock Jumped 83% Today

By George Budwell - Sep 16, 2015 at 11:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive late-stage data readout sent Intra-Cellular Therapies' stock soaring today.

What: Shares of Intra-Cellular Therapies (ITCI -3.09%), a biopharma developing treatments for disorders of the central nervous system(ITCI -3.09%) rose by as much as 83% today on tremendous volume:

ITCI Price Chart

This rocket-like rise in share price was brought about by a positive data readout for the company's late-stage experimental drug, ITI-007, indicated for the treatment of schizophrenia. 

According to the press release, patients in the intent-to-treat study population showed a statistically significant improvement on their Positive and Negative Syndrome Scale total score (PANSS) compared to those receiving placebo. Put simply, patients on the drug exhibited fewer overall symptoms associated with schizophrenia, relative to those taking a placebo.

Another key issue is that the drug didn't result in any meaningful changes across a diversity of potential side effects common to medicines used to treat schizophrenia, according to the company. 

So what: Schizophrenia is a serious mental illness with inadequate therapeutic options at present. The currently available medicines only treat a handful of the disorder's symptoms, and also come with a host of problematic side effects. Intra-Cellular Therapies is thus hoping that ITI-007 can meed this unmet medical need.  

Now what: This study is the first of two planned late-stage studies to assess ITI-007 in schizophrenia. While the details on the second study are sparse at the moment, the market is obviously encouraged by the fact that the drug's late-stage results are broadly similar to those from its prior mid-stage trial. In other words, the market appears to think that ITI-007 is largely "de-risked" as a schizophrenia treatment following these impressive results. Given the strong likelihood that a capital raise is going to be coming down the pike soon, though, investors that missed this massive run-up may not want to chase this stock today. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intra-Cellular Therapies, Inc. Stock Quote
Intra-Cellular Therapies, Inc.
ITCI
$57.36 (-3.09%) $-1.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.